Literature DB >> 21419167

Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.

Elisa Soprana1, Maddalena Panigada, Mathias Knauf, Antonia Radaelli, Luisa Vigevani, Alessio Palini, Chiara Villa, Mauro Malnati, Giulia Cassina, Reinhard Kurth, Stephen Norley, Antonio G Siccardi.   

Abstract

Pairs of recombinant MVA (Modified Vaccinia Ankara) and FPV (Fowlpox Virus) expressing the same transgene are reasonable candidates for prime/boost regimens, because cross-reacting immune responses between the two vectors, both non-replicative in mammalian hosts, are very limited. The acceptor virus FPD-Red, a derivative of FPV, carrying a red fluorescent protein gene flanked by the homology regions of MVA deletion III, was constructed. The same MVA Transfer Plasmid Green, designed to insert transgenes into the MVA deletion III locus, can therefore be used to transfer transgenes into both acceptor viruses MVA-Red and FPD-Red with the described recently Red-to-Green gene swapping method. Cells infected by either recombinant virus can be sorted differentially by a simple and reliable FACS-based purification protocol. The procedure is carried out in primary chick embryo fibroblasts grown in serum-free media and was applied to the production of three rMVA/rFPV pairs expressing the H5N1 avian influenza antigens M1, M2 and NP. The viral genes were human codon-optimized and expressed at high levels in both chick and mammalian cells. Both single-step and multiple-step growth analyses showed no significant differences in growth due to the transgenes in either rMVA or rFPV derivatives.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419167     DOI: 10.1016/j.jviromet.2011.03.013

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Authors:  Peter R Hoffmann; Maddalena Panigada; Elisa Soprana; Frances Terry; Ivo Sah Bandar; Andrea Napolitano; Aaron H Rose; Fukun W Hoffmann; Lishomwa C Ndhlovu; Mahdi Belcaid; Lenny Moise; Anne S De Groot; Michele Carbone; Giovanni Gaudino; Takashi Matsui; Antonio Siccardi; Pietro Bertino
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Authors:  Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

3.  Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein.

Authors:  Xiaomin Yuan; Huixing Lin; Hongjie Fan
Journal:  Vaccine       Date:  2015-06-23       Impact factor: 3.641

4.  Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.

Authors:  Massimiliano Bissa; Sole Maria Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen; Elena Illiano; Francesca Granucci; Ivan Zanoni; Achille Broggi; Antonia Radaelli
Journal:  Virus Res       Date:  2013-09-16       Impact factor: 6.286

5.  Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.

Authors:  Massimiliano Bissa; Elena Quaglino; Carlo Zanotto; Elena Illiano; Valeria Rolih; Sole Pacchioni; Federica Cavallo; Carlo De Giuli Morghen; Antonia Radaelli
Journal:  Antiviral Res       Date:  2016-09-13       Impact factor: 10.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.